Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 4
2014 3
2015 1
2019 2
2021 2
2022 2
2023 1
2024 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines.
Pothast CR, Hofsink Q, Haggenburg S, Dijkland RC, Van de Meent M, Van Dijk K, Bhoekhan MS, Haverkate NJE, Van Meerloo J, Falkenburg JHF, De Groen RAL, Broers AEC, Van Doesum JA, Van Binnendijk RS, Den Hartog G, Lissenberg-Witte BI, Kater AP, Smits GP, Wouters D, Van Leeuwen EMM, Bontkes HJ, Kootstra NA, Vogels-Nooijen S, Van Baarle D, De Vries RD, Van Meerten T, Mutsaers PGNJ, Goorhuis A, Nijhof IS, Hazenberg MD, Heemskerk MHM, Rutten CE, Study Team CK. Pothast CR, et al. Among authors: smits gp. Haematologica. 2025 Nov 1;110(11):2799-2805. doi: 10.3324/haematol.2024.287136. Epub 2025 May 29. Haematologica. 2025. PMID: 40438989 Free PMC article. No abstract available.
Protective mucosal SARS-CoV-2 antibodies in the majority of the general population in the Netherlands.
Verheul MK, Kaczorowska J, Hofstee MI, Schepp RM, Smits GP, Wessels Beljaars D, Kuijer M, Schuin W, Middelhof I, Wong D, van Hagen CCE, Vos ERA, Nicolaie MA, de Melker HE, van Binnendijk RS, van der Klis FRM, den Hartog G. Verheul MK, et al. Among authors: smits gp. Mucosal Immunol. 2024 Aug;17(4):554-564. doi: 10.1016/j.mucimm.2024.03.008. Epub 2024 Mar 27. Mucosal Immunol. 2024. PMID: 38553008 Free article.
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
Hofsink Q, Haggenburg S, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, van Meerloo J, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Vogels-Nooijen S, Rots N, van Beek J, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI study team. Hofsink Q, et al. Among authors: smits gp. EClinicalMedicine. 2023 Jul;61:102040. doi: 10.1016/j.eclinm.2023.102040. Epub 2023 Jun 15. EClinicalMedicine. 2023. PMID: 37337616 Free PMC article.
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Zweegman S, Kater AP, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, Beaumont T, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI Study Team. Haggenburg S, et al. Among authors: smits gp. JAMA Oncol. 2022 Oct 1;8(10):1477-1483. doi: 10.1001/jamaoncol.2022.3227. JAMA Oncol. 2022. PMID: 35951338 Free PMC article.
19 results